Giacomo Matteo Bruno (Giacomo M Bruno)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Venues

ClinicoEconomics and outcomes research : CEOR

Pragmatic and observational research

Therapeutics and clinical risk management

Risk management and healthcare policy

S.A.V.E. STUDI ANALISI VALUTAZIONI ECONOMICHE

This page only lists publications with an associated author ORCID identifier.

Affiliation History

S.A.V.E. STUDI ANALISI VALUTAZIONI ECONOMICHE Mar 02 2011

Italy

Project Development Manager & Associate Consultant

Publications

Sergio Di Matteo, Roberto Freilone, Giacomo Matteo Bruno, Rosario Notaro, Sabrin Moumene, Nicoletta Martone, Cristina Teruzzi, Antonio Ciccarone, Giorgio Lorenzo Colombo
Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria. ClinicoEconomics and outcomes research : CEOR 16 (2024)
Sergio Di Matteo, Roberto Freilone, Giacomo Matteo Bruno, Rosario Notaro, Sabrin Moumene, Nicoletta Martone, Cristina Teruzzi, Antonio Ciccarone, Giorgio Lorenzo Colombo
Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria. ClinicoEconomics and outcomes research : CEOR 16 (2024)
Francesco Pesce, Giacomo Matteo Bruno, Giorgio Lorenzo Colombo, Sergio Di Matteo, Anna Rita Maurizi, Valentina Mongelli, Silvia Mele, Lavinia Narici, Stefano Bianchi, Mario Bonomini, Giuseppe Castellano, Luca De Nicola, Giovanni Gambaro, Giuseppe Grandaliano, Gaetano La Manna, Antonello Pani, Andrea Ranghino, Loreto Gesualdo
Clinical and Economic Impact of Early Diagnosis of Chronic Kidney Disease in General Practice: The Endorse Study. ClinicoEconomics and outcomes research : CEOR 16 (2024)
Sergio Di Matteo, Roberto Freilone, Giacomo Matteo Bruno, Rosario Notaro, Sabrin Moumene, Nicoletta Martone, Cristina Teruzzi, Antonio Ciccarone, Giorgio Lorenzo Colombo
Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria. ClinicoEconomics and outcomes research : CEOR 16 (2024)
Francesco Pesce, Giacomo Matteo Bruno, Giorgio Lorenzo Colombo, Sergio Di Matteo, Anna Rita Maurizi, Valentina Mongelli, Silvia Mele, Lavinia Narici, Stefano Bianchi, Mario Bonomini, Giuseppe Castellano, Luca De Nicola, Giovanni Gambaro, Giuseppe Grandaliano, Gaetano La Manna, Antonello Pani, Andrea Ranghino, Loreto Gesualdo
Clinical and Economic Impact of Early Diagnosis of Chronic Kidney Disease in General Practice: The Endorse Study. ClinicoEconomics and outcomes research : CEOR 16 (2024)
Giorgio Lorenzo Colombo, Maria Chiara Valentino, Alessandra Fabi, Maria Vittoria Dieci, Mauro Caruggi, Giacomo Matteo Bruno, Gloria Lombardi, Sergio Di Matteo
Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy. Therapeutics and clinical risk management 19 (2023)
Giacomo Matteo Bruno, Maria Chiara Valentino, Alessandra Brunetti, Sergio Di Matteo, Ivan Begovic, Edoardo Croce, Garifallia Sakellariou, Serena Bugatti, Pietro Perotti, Silvia Vecchio, Simona Migliazza, Roberto Langella, Giorgio Lorenzo Colombo
Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia. Pragmatic and observational research 14 (2023)
Giacomo Matteo Bruno, Maria Chiara Valentino, Alessandra Brunetti, Sergio Di Matteo, Ivan Begovic, Edoardo Croce, Garifallia Sakellariou, Serena Bugatti, Pietro Perotti, Silvia Vecchio, Simona Migliazza, Roberto Langella, Giorgio Lorenzo Colombo
Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia. Pragmatic and observational research 14 (2023)
Enrico Torre, Sergio Di Matteo, Giacomo Matteo Bruno, Chiara Martinotti, Maria Chiara Valentino, Gianni Testino, Alberto Rebora, Luigi Carlo Bottaro, Giorgio Lorenzo Colombo
Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives. ClinicoEconomics and outcomes research : CEOR 14 (2022)
Enrico Torre, Giorgio Lorenzo Colombo, Sergio Di Matteo, Chiara Martinotti, Maria Chiara Valentino, Alberto Rebora, Francesca Cecoli, Eleonora Monti, Marco Galimberti, Paolo Di Bartolo, Germano Gaggioli, Giacomo Matteo Bruno
Economic Impact of COVID-19 Lockdown on Italian NHS: Focus on Diabetes Mellitus. ClinicoEconomics and outcomes research : CEOR 13 (2021)
Enrico Torre, Giacomo Matteo Bruno, Sergio Di Matteo, Chiara Martinotti, Maria Chiara Valentino, Luigi C Bottaro, Giorgio Lorenzo Colombo
Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study. ClinicoEconomics and outcomes research : CEOR 12 (2020)
Giorgio Walter Canonica, Giorgio Lorenzo Colombo, Rogliani Paola, Pierachille Santus, Claudia Pitotti, Sergio Di Matteo, Chiara Martinotti, Giacomo Matteo Bruno
Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study. Risk management and healthcare policy 13 (2020)

Giacomo Matteo Bruno.css-eqlu8i{font-size:small;padding-left:4px;} (Giacomo M Bruno)

Publication Activity (10 Years)

Top Topics

Top Venues

Giacomo Matteo Bruno (Giacomo M Bruno)